Srinivas  Akkaraju net worth and biography

Srinivas Akkaraju Biography and Net Worth

Srinivas Akkaraju, M.D., Ph.D. has served as a member of our Board of Directors since October 2012. Since March 2017, Dr. Akkaraju has been the Managing General Partner of Samsara BioCapital, a venture capital firm that he founded. From April 2013 to March 2017, Dr. Akkaraju was a General Partner and then a Senior Advisor of Sofinnova Ventures, a venture capital firm focused on the life sciences industry. From January 2009 until April 2013, Dr. Akkaraju was a Managing Director of New Leaf Venture Partners, an investment firm focused on the healthcare technology sector. From 2006 to 2008, Dr. Akkaraju served as a Managing Director of Panorama Capital, a venture capital firm that he co-founded along with other members of the former venture capital investment team of J.P. Morgan Partners, a private equity division of JPMorgan Chase & Co. Prior to co-founding Panorama Capital, Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a partner in 2005. From 1998 to 2001, Dr. Akkaraju worked in business and corporate development at Genentech, Inc. (now a member of the Roche Group), a biotechnology company. Dr. Akkaraju has been a director of Jiya Acquisition Corp. (where he also serves as Chairman) since November 2020, and Syros Pharmaceuticals, Inc. since June 2017. Dr. Akkaraju also serves on the board of directors of a number of private companies. Dr. Akkaraju received his M.D. and a Ph.D. in Immunology from Stanford University. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University.

What is Srinivas Akkaraju's net worth?

The estimated net worth of Srinivas Akkaraju is at least $33.94 million as of December 21st, 2023. Dr. Akkaraju owns 1,786,427 shares of Intercept Pharmaceuticals stock worth more than $33,942,113 as of April 26th. This net worth approximation does not reflect any other investments that Dr. Akkaraju may own. Learn More about Srinivas Akkaraju's net worth.

How do I contact Srinivas Akkaraju?

The corporate mailing address for Dr. Akkaraju and other Intercept Pharmaceuticals executives is 10 Hudson Yards 37th FL, New York NY, 10001. Intercept Pharmaceuticals can also be reached via phone at (646) 747-1000 and via email at [email protected]. Learn More on Srinivas Akkaraju's contact information.

Has Srinivas Akkaraju been buying or selling shares of Intercept Pharmaceuticals?

Srinivas Akkaraju has not been actively trading shares of Intercept Pharmaceuticals during the last quarter. Most recently, on Friday, March 12th, Srinivas Akkaraju bought 147,000 shares of Intercept Pharmaceuticals stock. The stock was acquired at an average cost of $21.29 per share, with a total value of $3,129,630.00. Following the completion of the transaction, the director now directly owns 23,121 shares of the company's stock, valued at $492,246.09. Learn More on Srinivas Akkaraju's trading history.

Who are Intercept Pharmaceuticals' active insiders?

Intercept Pharmaceuticals' insider roster includes Srinivas Akkaraju (Director), and David Shapiro (Insider). Learn More on Intercept Pharmaceuticals' active insiders.

Srinivas Akkaraju Insider Trading History at Intercept Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/12/2021Buy147,000$21.29$3,129,630.0023,121View SEC Filing Icon  
3/10/2021Buy90,000$20.96$1,886,400.0023,121View SEC Filing Icon  
8/28/2019Buy5,207$60.32$314,086.2421,526View SEC Filing Icon  
8/22/2019Buy67,784$66.37$4,498,824.08View SEC Filing Icon  
2/19/2019Sell23,438$128.78$3,018,345.64View SEC Filing Icon  
11/12/2014Buy2,000$167.19$334,380.00View SEC Filing Icon  
1/16/2014Sell3,250$267.94$870,805.001,943View SEC Filing Icon  
See Full Table

Srinivas Akkaraju Buying and Selling Activity at Intercept Pharmaceuticals

This chart shows Srinivas Akkaraju's buying and selling at Intercept Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Intercept Pharmaceuticals Company Overview

Intercept Pharmaceuticals logo
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Read More

Today's Range

Now: $19.00
Low: $19.00
High: $19.00

50 Day Range

MA: $18.88
Low: $18.20
High: $19.00

2 Week Range

Now: $19.00
Low: $8.82
High: $21.86

Volume

N/A

Average Volume

1,362,029 shs

Market Capitalization

$794.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88